CASPOFUNGIN DEMOGEN (Demogen Australia Pty Ltd trading as DEMOGEN Pharmaceuticals)
Product name
CASPOFUNGIN DEMOGEN
Date registered
Evaluation commenced
Decision date
Approval time
116 (255 working days)
Active ingredients
caspofungin acetate
Registration type
New generic medicine
Indication
CASPOFUNGIN DEMOGEN is indicated for:
- Empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics
- Treatment of:
- Invasive Candidiasis, including candidaemia
- Oesophageal Candidiasis
- Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies.